secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-031669
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Q1 net loss $19.9M, cash $183.6M; FHD-909 Phase 1 on track; IND for two degraders expected 2027
--------------------------------------------------------------------------------

- Q1 2026 net loss $19.9M (vs $18.8M loss Q1 2025); collaboration revenue $3.3M (down from $6.0M).
- Cash, equivalents & marketable securities $183.6M as of Mar 31, 2026; cash runway into H1 2028.
- Lead program FHD-909 Phase 1 dose-escalation on track; preclinical combo with anti-PD-1 showed complete tumor regression and immune memory.
- IND expected 2027 for Selective CBP degrader FHT-171 and Selective EP300 degrader; ARID1B degrader advancing to in vivo proof-of-concept in 2026.
- R&D expenses declined to $18.3M (from $21.6M) driven by lower Lilly-partnered program costs and facilities expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026031669/0001628280-26-031669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828026031669/fhtx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-031669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer